about
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.Measuring the preventability of adverse drug reactions in France: A 2015 overview.Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey.[Necrotizing enterocolitis in a full-term infant. Is acyclovir involved?][Preventability of adverse effects in a medical emergency service][New methods for studying drug associated risk: experience of the Toulouse Regional Pharmacovigilance Center].Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs.[Drug-related neuropathies: analysis of the French Adverse Drug Reaction Database 1995-2005].Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.[Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale].[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].Assessing the Feasibility of Using an Adverse Drug Reaction Preventability Scale in Clinical PracticeAcute Coronary Syndrome After Nasal Spray of Oxymetazoline[Adverse cardiovascular and central neurologic reactions to sympathomimetics used as nasal decongestants: results of the French National Pharmacovigilance Survey]Gynecomastia associated with fenofibrateNeuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of viewThe nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in FranceIs spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?[Post-marketing safety profile of avocado-soybean unsaponifiables]Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer
P50
Q35057254-B1981BC5-4CB8-4A9F-8D84-25F1368782BAQ36655440-A86D69EC-3936-4A44-8179-A5CA7B2DAAF4Q40799109-D0012866-B196-44CD-A4A0-8228399FFBCCQ43641363-369FEA3F-2B92-4E57-8369-3F58C25F0CA4Q44187841-5408576E-C6AE-4741-A16E-FCF5D130D482Q44320865-7EE08EB2-A237-4E8F-8732-6F9B2C071A18Q46692112-F2CAE5A5-8EEB-49EB-87ED-58EB03C1A875Q46763793-C036342A-2AE6-456E-A614-50D69640B431Q46776671-E0A1AA24-6FA2-4FCE-ACF3-B1708E741668Q49993370-D5CAB426-5FC3-4626-A1F4-7C96F050D0E2Q52978326-6C8E0E17-A475-4FAE-B3B6-24025F8559F2Q54692964-2F760E22-3558-4850-92CF-BC3320A90DB0Q60619208-90DBE862-53AF-4317-880F-D3F621D143EEQ61314463-CC749E06-AFEB-4A1A-9AD5-2665DEA3B7CCQ79370722-A6CB753C-2D63-4299-9760-AF38B88BD5C4Q79886686-923D361B-06D2-4DE4-AD25-4C1DF53A55DEQ83158072-CE11BE80-DBD6-4C3C-9E1D-2A04BB026F8DQ83341067-D82A7C0F-9947-49D9-9302-FA4B07EA6CCBQ84954436-8ED6ACE6-C208-4325-9C60-378B9010C0EAQ85179688-CAA05DE3-20D1-4D0C-BBFB-5F9984AA16E1Q92614283-5085DF68-F0D3-44DA-A393-F2B25936D9B9
P50
description
researcher ORCID ID = 0000-0002-1801-9581
@en
wetenschapper
@nl
name
Pascale Olivier
@ast
Pascale Olivier
@en
Pascale Olivier
@es
Pascale Olivier
@nl
type
label
Pascale Olivier
@ast
Pascale Olivier
@en
Pascale Olivier
@es
Pascale Olivier
@nl
prefLabel
Pascale Olivier
@ast
Pascale Olivier
@en
Pascale Olivier
@es
Pascale Olivier
@nl
P106
P21
P31
P496
0000-0002-1801-9581